ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

February 14, 2026

Study Completion Date

August 14, 2026

Conditions

RAS MutationMetastatic Colorectal CancerMSS

Interventions

DRUG

irinotecan, cetuximab, envafolimab

rechallenge treatment

Trial Locations (1)

RECRUITING

Beijing Hospital, Beijing

All Listed Sponsors

collaborator

Bethune Charitable Foundation

UNKNOWN

lead

Beijing Hospital

OTHER_GOV